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Pregnant women with diabetes often require preterm delivery. Antenatal betamethasone 
reduces perinatal morbidity and mortality, but induces hyperglycemia. The primary objective 
was to observe glucose excursions and determine the preliminary safety of a protocol for 
subcutaneous insulin following betamethasone administration in an antenatal ward. 
Material and Methods 
This retrospective study included all women with diabetes who received betamethasone due 
to imminent preterm delivery. Glucose excursions were evaluated in the fasting state and 
two-hours postprandial. Blood glucose values ≥14mmol/L or ≤3.5mmol/L were regarded as 
unacceptable hyper- and hypoglycemia respectively. Events over the first 96 hours were 
documented. 
Results 
This study spanned 52 months and included fifty-nine women. Eleven episodes of defined 
hypoglycemia occurred in six women, all receiving insulin therapy, but none after a corrective 
dose of insulin. No serious hypoglycemic incident was reported. Seventeen women 
experienced hyperglycemic incidents almost entirely (47/56) within 48 hours of 
betamethasone administration, most often postprandially (34/56) and in 85% of episodes, 
preceded by pre-prandial values >9 mmol/L (29/34).  Fourteen (82.4%) of these women were 
receiving background insulin therapy. No case with gestational diabetes encountered defined 
hyperglycemia. 
Conclusions 
This small study demonstrated preliminary safety of the protocol. Enhanced surveillance is 
necessary for 72 hours after initiation of betamethasone. 
  
Introduction 
Obesity is a major health challenge. Globally, the percentage of adult women who are 
overweight increased from 29.8% in 1980 to 38% in 2013 [1]. In South Africa, more than a 
third of women are considered obese, and trends of obesity in this population have mirrored 
the rest of the world [1,2]. Furthermore, women are often delaying pregnancy. Consequently, 
the pregnant population is now heavier and older than before [3]. 
Maternal obesity increases adverse pregnancy outcomes such as hypertensive disorders, 
gestational diabetes, surgical complications, as well as fetal and neonatal complications [4]. 
The prevalence of diabetes in pregnancy is about 16.9% globally [5], being the most common 
medical disorder of pregnancy [6]. 
Preterm birth is a global problem [7], with spontaneous or iatrogenic, preterm delivery 
occurring in up to 20% of pregnancies with diabetes [6]. Complications of diabetes in 
pregnancy associated with early delivery include hypertension, infections, intra-uterine 
growth restriction and polyhydramnios. Preterm birth has significant health implications for 
the newborn such as neonatal death, respiratory distress syndrome, intraventricular 
hemorrhage and necrotizing enterocolitis. These infants may be more prone to pulmonary 
immaturity than infants of non-diabetic pregnancies through an independent disease-related 
effect [8]. 
Antenatal corticosteroid administration before preterm delivery dramatically improves 
perinatal outcomes, being supported by robust clinical trials [7, 9]. When preterm delivery 
threatens a pregnancy complicated by diabetes, it is reasonable to assume that these babies 
stand to benefit as much, or more, from corticosteroid therapy [10].  However, corticosteroids 
induce hyperglycemia [11]. Pregnancy is characterized by relative glucose intolerance and 
insulin resistance; thus, addition of high dose corticosteroids may cause significant disruption 
in glucose control in women with diabetes. This hyperglycemia increases the risk of 
ketoacidosis and may cause fetal acidosis and compromise. Research shows that significant 
amounts of supplementary insulin are required to control blood glucose levels in the initial 
period following high dose corticosteroid therapy [10]. This raises the question of how 
supplementary insulin should be administered, whether by continuous intravenous or 
subcutaneous infusions, or using an adapted basal bolus regimen [12]. Ideally, patients should 
be admitted into a high-dependency setting, with careful maternal and fetal monitoring. Such 
units are, however, a scarce resource in low- to middle-income countries.  
Clinical trials to assess the safety of antenatal corticosteroids have traditionally excluded 
subgroups of women with confounding conditions, such as diabetes. There is thus a lack of 
consistent, evidence-based guidance, creating barriers to effective management. A review 
published in 2016 identified no eligible studies on preterm birth outcomes following antenatal 
corticosteroid therapy in pregnancies complicated by diabetes [8]. 
This study aimed to assess the preliminary safety of a local protocol for intermittent 
subcutaneous insulin following antenatal betamethasone administration to pregnant women 
with diabetes in a standard ward at Tygerberg Hospital, South Africa. 
Materials and Methods 
This study was a retrospective audit, in the Obstetric Special Care (OSC) ward at Tygerberg 
Hospital, a secondary/tertiary referral center. All women with diabetes and at significant risk 
of preterm delivery were admitted to this unit. The study population included all such 
pregnancies that received a course of antenatal betamethasone (12mg IM repeated once 
after 24 hours) and were managed according to the local protocol for pre-prandial corrected 
subcutaneous insulin (Figure 1). No exclusion criteria were identified. 
 
 
Figure 1. Local protocol for pre-prandial bolus insulin correction doses in management of 
hyperglycemia in pregnant women with diabetes during betamethasone administration. *yellow 
coded insulin = short-acting human insulin, BG = blood glucose 
 
Diabetes was classified as pregestational Types 1 and 2, gestational diabetes and undiagnosed 
pregestational diabetes detected for the first time in pregnancy.  Gestational diabetes was 
diagnosed using a fasting capillary glucose (CG) level ≥5.6 mmol/L or a 2-hour postprandial 
level ≥7.8 mmol/L. As formal 75g OGTTs are not performed in our setting, the 2-hour value 
was taken after the patient had consumed her own breakfast. In cases with no history of 
diabetes, when the fasting CG was ≥7 mmol/L, or the 2-hour postprandial level ≥11.1 mmol/L, 
or the HbA1c ≥6.5% (≥48 mol/mmol), the patient was classified as undiagnosed pregestational 
diabetes. For further interpretation patients were divided into two main diabetes sub-classes, 
namely those with Type 1 diabetes and ‘others,’ which included known or suspected Type 2 
diabetes and true gestational diabetes. 
Treatment before admission included lifestyle modification, metformin and insulin as 
appropriate [13]. The local protocol for pre-prandial corrected rapid-acting, subcutaneous 
insulin was applied whatever form of treatment the patient was receiving at the time of 
inpatient betamethasone administration. Initiation of betamethasone therapy was not 
confined to any specific time of day. Fasting, pre-prandial, two-hour postprandial, and 02h00 
capillary samples were recorded for 96 hours thereafter. No venous samples were drawn. All 
capillary samples were measured with the same Accu-chek Active® hand-held machine and 
measuring strip codes were confirmed before each measurement. Care was also exercised to 
limit any contamination of the sample. The finger used for the measurement was cleaned 
with water and thoroughly dried. The Accu-check Active® device and test strips determine 
blood glucose concentration by reflectance photometry and according to the Roche® package 
insert, the device is calibrated (corrected) to reflect plasma levels even though whole blood 
is applied to the test strip. The analytical performance has previously been evaluated against 
rigorous laboratory criteria and did not exceed total allowable error in the fasting or 
postprandial state [14]. 
The primary aim was to ascertain preliminary safety when antenatal betamethasone was 
administered to pregnant women with diabetes outside of a dedicated high-care 
environment. Safety was evaluated based on the documentation of hypo- or hyperglycemia 
in the fasting state (02h00 and early morning before breakfast) and two-hours postprandial 
for breakfast, lunch and supper. A CG value ≤3.5 mmol/L indicated hypoglycemia with safety 
concerns. A CG value ≥14 mmol/L at any of the mentioned time points was regarded as 
unacceptable hyperglycemia with significant risk for the development of keto-acidosis.  
Hypoglycemia was further defined using the classification of the American Diabetes 
Association in their 2018 consensus paper regarding glycemic targets [15]. A serious 
hypoglycemic episode is not linked to any specific glucose threshold, but implies 
hypoglycemia associated with severe cognitive impairment requiring external assistance for 
recovery. A blood glucose value below 3 mmol/L is regarded as clinically significant 
hypoglycemia. Patients manifesting with hyper- or hypoglycemia and the total numbers of 
hyper- and hypoglycemic events over the first 96 hours were documented. Safety was 
evaluated for the total cohort and the different diabetes types (Type 1 diabetes mellitus, Type 
2 diabetes mellitus and gestational diabetes). 
Secondary outcomes included the impact of diabetes type (Type 1 DM versus others) on 
safety, the appropriateness of the surveillance period, the efficacy of the protocol and overall 
compliance to the protocol. The appropriateness of the surveillance period of 96 hours 
following the first dose of betamethasone was evaluated for the total cohort and the different 
diabetes subtypes, based on the number of corrective doses.  Finally, adherence and 
compliance with the proposed protocol was assessed based on the number of correction 
doses given or omitted and if given, how many were accurate in accordance with the protocol. 
Data were collected by the principal investigator from electronic and hard-copy records and 
transferred onto an anonymized data sheet with case numbers only.  Three attempts were 
made before classifying records as lost. Statistical analysis was conducted using the Statistica 
(version 13, StatSoft) program. The Kolmogorov-Smirnov (K-S) normality test with Lilliefors 
correction was used (p<0.05) and normal distribution confirmed with the Shapiro-Wilk test. 
Results are reported as either n (%), means (SD) (normally distributed) and/or median (range) 
(non-parametric data). In cases where data were not normally distributed, non-parametric 
Kruskal-Wallis ANOVA with Dunns multiple comparison test was used to determine 
differences between groups and time.  A probability value (p-value) of <0.05 was regarded 
was significant.  
The study was approved with the Human Research and Ethics Committee of Stellenbosch 
University (S16/10/195). 
Results 
The study spanned 52 months (01/11/2013 to 28/02/2018).  Sixty-two women with diabetes 
at significant risk of preterm delivery and/or pulmonary immaturity received an antenatal 
course of betamethasone in the OSC ward.  Two cases were excluded due to irretrievable data 
and one for protocol violation, leaving 59 for analysis.  The descriptive data are given in Table 
1. 
No serious hypoglycemic episode was encountered. Eleven hypoglycemia values (CG ≤3.5 
mmol/L) occurred in six patients, with episodes for a single case ranging from 1-3. Four 
episodes were documented in the fasting state before breakfast, whereas no hypoglycemic 
values were noted at the 02h00 time point and only three hypoglycemic episodes occurred 
postprandially (3.4-3.5 mmol/L). None of the latter three episodes occurred after a corrective 
dose of insulin.  Clinically significant hypoglycemia (CG <3 mmol/L) occurred pre-prandially at 
breakfast and lunch on day three in a single patient with Type 1 diabetes. 
Unacceptable hyperglycemic episodes (≥14 mmol/L) occurred in 17 (28.8%) women, with 56 
episodes (14 fasting or pre-prandial, 34 postprandial and 8 at 02h00), the range of episodes 
for a single case being 1-13. The majority of hyperglycemic episodes thus occurred 
postprandially (60.7%) and were mostly preceded (85.3%) by pre-prandial CG measurements 
>9 mmol/L. Forty-seven of the hyperglycemic episodes (83.9%) happened during the first 48 
hours after initiation of betamethasone.  Nine hyperglycemic episodes occurred from 49-72 
hours and none from 73-96 hours. 
Hypoglycemia occurred in four patients with Type 1 and in two with Type 2 diabetes. The 
patients with Type 2 diabetes were both on insulin therapy preceding the study. Blood glucose 
values below 3 mmol/L were confined to a single patient with Type 1 diabetes and were 
documented pre-prandially at breakfast and lunch (values 2.4 and 2.9 mmol/L) on day 3. 
Hyperglycemia was documented in six women with Type 1 (6/15; 40%) and in 11 women with 
other diabetes mellitus subtypes (11/44; 25%). The vast majority of hyperglycemic episodes 
occurred in insulin-treated patients (14/17; 82.4%). None of the women with true Gestational 




Table 1. Baseline characteristics of patients (n = 59) 
HbA1C reported according to the National Glycohemoglobin Standardization Programme (NGSP) as a 
% and as mol/mmol according to the International Federation of Clinical Chemistry (IFCC). PPROM = 
preterm pre-labor rupture of membranes; PTL = preterm labor; placental dysfunction = umbilical 
artery Doppler velocimetry ≥95th centile; Diabetes “Other types” include Type 2 and gestational 
diabetes, as well as those with undiagnosed pregestational diabetes mellitus. 
Description Mean (SD), median# or n (%)* Range 
General   
Age (years) 32.8 (5.8) 20-44 
BMI (kg/m2) 32.4 (6.9) 20-50 
Gravidity#  3 1-8 
Parity# 2 0-6 
Gestation - betamethasone (weeks)# 30 25-38 
Diabetes class n (%)   
Type 1  15 (25.4%)  
Other types 44 (74.6%)  
          Type 2 28 (47.5%)  
          Gestational 7 (11.9%)  
          Undiagnosed pregestational 9 (15.3%)  
Diabetes treatment n (%)   
Lifestyle only 
o Total cohort  
o        Type 1  
o        Other types  
 
2 of 59 (3.4%) 
0 of 15 (0.0%) 
2 of 44 (4.5%) 
 
Lifestyle + metformin 
o Total cohort 
o       Type 1 
o       Other types 
 
17 of 59 (28.8%) 
0 of 15 (0.0%) 
17 of 44 (38.6%) 
 
Insulin 
o Total cohort 
o      Type 1 
o      Other types  
 
40 of 59 (67.8%) 
15 of 15 (100.0%) 
25 of 44 (56.8%) 
 
HbA1c before admission 
   NGSP (%) 






27.9 – 98.9 
Comorbid metabolic abnormalities   
  Obesity (BMI 30kg/m2) 
o Type 1 
o Other types  
42 of 59 (71.2%) 
4 of 15 (26.7%) 
38 of 44 (86.4%) 
 
  Hypertensive disorders 
o Chronic hypertension 
o Pre-eclampsia 
o Superimposed pre-eclampsia 
39 of 59 (66.1%) 
11 of 39 (28.2%) 
17 of 39 (43.6%) 
11 of 39 (28.2%) 
 
Other comorbid conditions   
o PPROM or PTL 18 of 59 (30.5%)  
o Placental dysfunction 10 of 59 (16.9%)  
o Multiple pregnancy  5 of 59 (8.5%)  
The median fasting, 02h00 and highest postprandial values for all cases are shown in Figure 
2. Postprandial values following breakfast, lunch and supper are tabulated in Table 2 for the 
observation period (T1-T4 = 4 x 24-hour periods) for all cases (n=59), patients with Type 1 
(n=15) and the other diabetes subtypes (n=44) respectively. For the observation period (T1-
T4), peak blood glucose values were noted during T1 and T2 (within 48 hours after the first 
and within 24 hours after the second betamethasone injection) (Figure 2). Blood glucose 
values returned to baseline on T3 and T4 for the fasting, 02h00 and all postprandial time 
points (Table 2). When subdivided into Type I diabetes versus other diabetes types, there 




Figure 2. Median capillary glucose values in women following betamethasone initiation during the 
surveillance period. T0=before betamethasone, T1 ≤ 24 hours, T2 = 25-48 hours, T3= 49-72 hours 
and T4 = 73-96 hours after first dose of betamethasone. Data illustrated as box- and whisker plots 









Table 2. Postprandial capillary glucose values over the observation period of 96 hours. 
Timing and DM subtype Blood glucose mmol/L: median (range) 
 T1 T2 T3 T4 
Breakfast 
    
o Total cohort 9.0 (5.3-15.5) 9.7 (4.6-33.3) 6.9 (4.0-17.5) 7.8 (4.1-10.7) 
o Type 1  11.0 (7.1-14.2)* 11.2 (5.3-15.1) 7.6 (4.1-13.6) 8.9 (4.8-10.7)* 
o Other types 8.9 (5.3-15.5)* 8.9 (4.6-33.3) 6.3 (4-17.5) 6.5 (4.1-10.5)* 
Lunch 
o Total cohort 8.5 (4.4-15.0) 8.3 (4.4-23.5) 7.3 (3.7-18.4) 6.3 (4.2-10.5) 
o Type 1  10.2 (4.4-14.0) 9.3 (4.7-15.5) 7.7 (4.4-18.4) 6.4 (5.1-9.8) 
o Other types 7.8 (4.7-15.0) 7.9 (4.4-23.5) 7.2 (3.7-12.5) 6.2 (4.2-10.5) 
Supper     
o Total cohort 9.8 (3.5-18.9) 10.2 (6.2-21.5) 7.9 (3.4-17.2) 6.7 (3.7-11.6) 
o Type 1 10.4 (3.5-14.3) 11.8 (7.0-20.0) 6.3 (3.4-13.8) 8.7 (4.1-11.0)* 
o Other types 9.5 (4.7-18.9) 9.4 (6.2-21.5) 8 (3.5-17.2) 6.4 (3.7-11.6)* 
T1 ≤ 24 hours, T2 = 25-48 hours, T3= 49-72 hours and T4 = 73-96 hours after first dose of 
betamethasone.  Diabetes “Others types” include Type 2 and gestational diabetes, as well as those 
with undiagnosed pregestational diabetes mellitus. Statistical analysis: Multiple comparisons 
Kruskal-Wallis ANOVA. *p<0.05 between Type 1 and the other diabetes subtypes at the same time 
point. 
 
Prandial glucose excursions over breakfast, lunch and supper are shown in Figure 3. Prandial 
excursions in excess of 2 mmol/L were limited to breakfast time and only noted during T1 and 
T4; with the peak average excursion being 2.2±1.7 mmol/L noted during T4. 
 
Figure 3. Mean prandial glucose excursions over mealtimes 
Overall compliance was 83% (497/598 time-points), ranging between 67% and 95% at 
different meal-times and during the 24-hour observation periods T1-T4 (Table 3). Most pre-
prandial insulin correction doses were required during T2 (92 doses) followed by T1 (75 
doses). The percentage of doses incorrectly omitted varied, with 56% during T1, 36% during 
T2 and T3 and 48% during T4. The accuracy of the given doses was 92% (120/130 doses given). 
The majority of missed doses (59%) occurred at the lowest step (8.0-9.9 mmol/L) of CG values 
prompting correction. Only two episodes of incorrect pre-prandial inulin dosing occurred at 
values below protocol criteria and in both instances only 2U were given. 
 
Table 3. Protocol compliance: Prandial insulin corrections at different time points over 96 
hours. 
 T1 T2 T3 T4 
Breakfast     
• doses given (n) 8 16 4 2 
• doses correctly omitted (n) 37 33 46 38 
• doses incorrectly omitted (n)* 13 (8) 8 (4) 3 (3) 2 (2) 
• accuracy of given corrections (%) 100% 94%  100% 50%  
• unknown datasets (n) 1 2 6 17 
• compliance to protocol (%) 78% (45/58) 86% (49/59) 95% (50/53) 95% (40/42) 
Lunch     
• doses given (n) 14 18 12 5 
• doses correctly omitted (n) 25 24 33 30 
• Doses incorrectly omitted (n)* 13 (7) 15 (7) 6 (3) 3 (3) 
• accuracy of given corrections (%)  92%  100% 92%  60%  
• unknown datasets 7 2 8 21 
• compliance to protocol (%) 75% (39/52) 74% (42/57) 88% (45/51) 92% (35/38) 
Supper     
• doses given (n) 11 25 13 4 
• doses correctly omitted (n) 21 19 30 29 
• Doses incorrectly omitted (n)* 16 (8) 10 (6) 7 (7) 5 (2) 
• accuracy of given corrections (%) 100% 92%  100% 50%  
• unknown datasets (n) 11 5 9 21 
• compliance to protocol (%) 67% (32/49) 81% (44/54) 86% (43/50) 87% (33/38) 
T1≤24 hours after first betamethasone, T2 = 25-48 hours after first betamethasone, T3= 49-72 hours 
after first betamethasone, T4 = 73-96 hours after first betamethasone. *Number of doses incorrectly 
omitted in parenthesis refers to omitted corrections with pre-prandial glucose values between 8-
9.9mmol/L. 
 
The median (range) gestation at delivery was 34 (27-38) weeks, while the mean birthweight 
was 1472 (SD±490) grams.  Only two babies (2%) had an Apgar score of less than seven, at 
five minutes. There were no intra-uterine deaths. 
 
Discussion 
Pregnant women with diabetes regularly face early preterm delivery. Antenatal 
betamethasone improves perinatal outcome, but elevates blood glucose necessitating careful 
management [16]. A systematic review in 2016 lamented the lack of evidence regarding safety 
of corticosteroids for women with diabetes [8].  
No serious hypoglycemia episode was observed in this study. Those on insulin were more 
likely to develop hypoglycemia but no case with true gestational diabetes developed 
hypoglycemia.  Defined hyperglycemia was encountered more readily, but never resulted in 
metabolic decompensation.  Hyperglycemia occurred predominantly within the first 48 hours 
after initiation of betamethasone. Special care is therefore advised during this period, 
especially in women already receiving insulin. As hyperglycemia may occur repeatedly, higher 
risk cases should be monitored more closely. The pre-prandial protocol was not devised to 
correct prior poor glycemic control in individuals, but rather to safely limit glucose elevations 
caused by betamethasone. 
Short-acting, subcutaneous insulin was used for the sake of simplicity. This contrasts with 
supplementary intravenous insulin infusions, also in wards by Kaushal et al., who required 
large amounts to achieve even moderate glycemic control [10].  Similarly, a Diabetes UK 
Position Statement advocates that hyperglycemia following steroid administration be 
managed by variable rate intravenous- or continuous subcutaneous insulin infusion [12].  
Most hyperglycemic episodes occurred postprandially and was almost invariably preceded by 
elevated pre-prandial values. Median prandial excursions were modest and within the 
allowed 2 mmol/L increase for all mealtimes.  These observations would support a 
conservative increase in basal insulin dosages during the T1 and T2 observation periods in 
women already on insulin, rather than intensifying the pre-prandial insulin correction 
protocol with potential excessive prandial lowering in blood glucose values.  No hypoglycemia 
was documented at 02h00 and the median glucose values for the total cohort and diabetes 
subtypes at this time point, argue that a conservative increase in basal insulin during the first 
48 hours, usually administered at bedtime, will be safe. This should especially be considered 
in patients presenting with hyperglycemia prior to betamethasone administration and those 
who manifest with pre- and postprandial hyperglycemia, early in the observation period. In 
describing their algorithm for insulin-dependent women receiving glucocorticoids for fetal 
lung maturation, Mathiesen et al, noted the individual doses of prandial and basal insulin 
before glucocorticoid injection. Then, for seven days, the doses of both insulin types were 
increased (up to 40% on days two and three) and thereafter gradually decreased back to pre-
glucocorticoid levels [17].  As in the index study, no cases of ketoacidosis or severe 
hypoglycemia were described.  
The duration of enhanced surveillance and dose adjustment is an important issue for 
institutions with a high demand for beds and limited resources. Mathiesen et al., described 
one week, while Kalra et al., proposed at least five days [18]. In the index study the most 
important period was the first 48 hours following the betamethasone initiation. The limited 
number of insulin corrections required during T4 and the absence of hyperglycemic episodes 
argues for the shortening of the observation period to 72 hours, especially in resource-
constrained settings, without adversely impacting safety.  The protocol was intentionally 
simple, but the importance of strict adherence to pre-prandial insulin corrections following 
betamethasone must be emphasized to caregivers, especially in a standard ward during the 
time periods mentioned. 
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